Sanofi said HHS has agreed to provide $43.2 million in funding forthe phase II development of an inactivated Zika vaccine. The French pharmaceutical company’s vaccines global business unit, Sanofi ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback